{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:55:43Z","timestamp":1779173743648,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Low adherence to investigational products can negatively impact study outcomes, limiting the ability to demonstrate efficacy. To continue advancing potential new HIV prevention technologies, efforts are needed to improve adherence among study participants. In MTN-020\/ASPIRE, a phase III randomized, double-blind, placebo-controlled study of the dapivirine vaginal ring carried out across 15 sites in sub-Saharan Africa, a multifaceted approach to adherence support was implemented, including a strong focus on participant engagement activities (PEAs). In this manuscript, we describe PEAs and participant attendance, and analyze the potential impact of PEAs on ring use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All sites implemented PEAs and submitted activity and attendance reports to the study management team throughout the study. Participant demographics were collected via case report forms. Residual dapivirine remaining in the last ring returned by each participant was used to estimate drug released from the ring, which was then adjusted for time participants had the ring to calculate probable use categorized into three levels (low\/intermittent\/high). Product use was connected to PEA attendance using participant identification numbers. We used multivariate Poisson regression with robust standard errors to explore differences in ring use between PEA attendance groups and reviewed qualitative reports for illustrative quotes highlighting participant experiences with PEAs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>2312 of 2629 study participants attended at least one of 389 PEAs conducted across sites. Participant country and partner knowledge of study participation were most strongly associated with PEA attendance (<jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.005) with age, education, and income status also associated with event attendance (<jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.05). When controlling for these variables, participants who attended at least one event were more likely to return a last ring showing at least some use (RR\u2009=\u20091.40) than those who never attended an event. There was a stronger correlation between a last returned ring showing use and participant attendance at multiple events (RR\u2009=\u20091.52).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our analysis supports the growing body of work illustrating the importance of meaningfully engaging research participants to achieve study success and aligns with other analyses of adherence support efforts during ASPIRE. While causation between PEA attendance and product use cannot be established, residual drug levels in returned rings strongly correlated with participant attendance at PEAs, and the benefits of incorporating PEAs should be considered when designing future studies of investigational products.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-021-11919-x","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T16:02:43Z","timestamp":1636387363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020\/ASPIRE study"],"prefix":"10.1186","volume":"21","author":[{"given":"Morgan","family":"Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Luecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley J.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Scheckter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Ndase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia Matovu","family":"Kiweewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen","family":"Kemigisha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petina","family":"Musara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila E.","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishanta","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kubashni","family":"Woeber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neetha S.","family":"Morar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitesha","family":"Jeenarain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zakir","family":"Gaffoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel K.","family":"Gondwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Makala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Llewellyn","family":"Fleurs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnaveni","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thesla","family":"Palanee-Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared M.","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane","family":"van der Straten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Soto-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Torjesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"11919_CR1","unstructured":"UNAIDS. Global HIV & AIDS Statistics - 2020 Fact Sheet [Internet] Geneva; 2020 [cited 2021 Feb 07]. Available from: http:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"issue":"9","key":"11919_CR2","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/17425247.2020.1783233","volume":"17","author":"DA Cobb","year":"2020","unstructured":"Cobb DA, Smith NA, Edagwa BJ, McMillan JM. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. Expert Opin Drug Deliv. 2020;17(9):1227\u201338. https:\/\/doi.org\/10.1080\/17425247.2020.1783233.","journal-title":"Expert Opin Drug Deliv"},{"issue":"22","key":"11919_CR3","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing Dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1506110.","journal-title":"N Engl J Med"},{"issue":"22","key":"11919_CR4","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","volume":"375","author":"A Nel","year":"2016","unstructured":"Nel A, van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, et al. Safety and efficacy of a Dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1602046.","journal-title":"N Engl J Med"},{"issue":"1","key":"11919_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1742-7622-6-5","volume":"6","author":"BR Masse","year":"2009","unstructured":"Masse BR, Boily MC, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol. 2009;6(1):5. https:\/\/doi.org\/10.1186\/1742-7622-6-5.","journal-title":"Emerg Themes Epidemiol"},{"issue":"5","key":"11919_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410. https:\/\/doi.org\/10.1056\/NEJMoa1108524.","journal-title":"N Engl J Med"},{"issue":"9883","key":"11919_CR7","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","volume":"381","author":"K Choopanya","year":"2013","unstructured":"Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(13)61127-7.","journal-title":"Lancet"},{"issue":"3","key":"11919_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","volume":"66","author":"D Donnell","year":"2014","unstructured":"Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340\u20138. https:\/\/doi.org\/10.1097\/QAI.0000000000000172.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"11919_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.atg.2012.07.001","volume":"1","author":"N Anderson","year":"2012","unstructured":"Anderson N, Bragg C, Hartzler A, Edwards K. Participant-centric initiatives: tools to facilitate engagement in research. Appl Transl Genom. 2012;1:25\u20139. https:\/\/doi.org\/10.1016\/j.atg.2012.07.001.","journal-title":"Appl Transl Genom"},{"issue":"5","key":"11919_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10461-014-0752-9","volume":"18","author":"LE Mansoor","year":"2014","unstructured":"Mansoor LE, Karim QA, Werner L, Madlala B, Ngcobo N, Cornman DH, et al. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial. AIDS Behav. 2014;18(5):841\u20138. https:\/\/doi.org\/10.1007\/s10461-014-0752-9.","journal-title":"AIDS Behav"},{"issue":"1","key":"11919_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.9734\/ISRR\/2013\/3531","volume":"1","author":"J Ambia","year":"2013","unstructured":"Ambia J. Barriers and facilitators of adherence in user-dependent HIV prevention trials, a systematic review. Int STD Res Rev. 2013;1(1):12\u201329. https:\/\/doi.org\/10.9734\/ISRR\/2013\/3531.","journal-title":"Int STD Res Rev"},{"issue":"6","key":"11919_CR12","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s10461-013-0429-9","volume":"17","author":"KR Amico","year":"2013","unstructured":"Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17(6):2143\u201355. https:\/\/doi.org\/10.1007\/s10461-013-0429-9.","journal-title":"AIDS Behav"},{"issue":"3","key":"11919_CR13","first-page":"14","volume":"16","author":"MM Holstad","year":"2012","unstructured":"Holstad MM, Essien JE, Ekong E, Higgins M, Teplinskiy I, Adewuyi MF. Motivational groups support adherence to antiretroviral therapy and use of risk reduction behaviors in HIV positive Nigerian women: a pilot study. Afr J Reprod Health. 2012;16(3):14\u201327.","journal-title":"Afr J Reprod Health"},{"issue":"1","key":"11919_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1080\/17441692.2012.699539","volume":"8","author":"P Walstrom","year":"2013","unstructured":"Walstrom P, Operario D, Zlotnick C, Mutimura E, Benekigeri C, Cohen MH. 'I think my future will be better than my past': examining support group influence on the mental health of HIV-infected Rwandan women. Global Public Health. 2013;8(1):90\u2013105. https:\/\/doi.org\/10.1080\/17441692.2012.699539.","journal-title":"Global Public Health"},{"issue":"2","key":"11919_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10461-017-1977-1","volume":"22","author":"ND Laborde","year":"2018","unstructured":"Laborde ND, Pleasants E, Reddy K, Atujuna M, Nakyanzi T, Chitukuta M, et al. Impact of the Dapivirine vaginal ring on sexual experiences and intimate partnerships of women in an HIV prevention clinical trial: managing ring detection and hot sex. AIDS Behav. 2018;22(2):437\u201346. https:\/\/doi.org\/10.1007\/s10461-017-1977-1.","journal-title":"AIDS Behav"},{"issue":"3","key":"11919_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/QAI.0000000000001503","volume":"76","author":"MJ Husnik","year":"2017","unstructured":"Husnik MJ, Brown ER, Marzinke M, Livant E, Palanee-Phillips T, Hendrix CW, et al. Implementation of a novel adherence monitoring strategy in a phase III, blinded, placebo-controlled, HIV-1 prevention clinical trial. J Acquir Immune Defic Syndr. 2017;76(3):330\u20137. https:\/\/doi.org\/10.1097\/QAI.0000000000001503.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"11919_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25634","volume":"23","author":"ER Brown","year":"2020","unstructured":"Brown ER, Hendrix CW, van der Straten A, Kiweewa FM, Mgodi NM, Palanee-Philips T, et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020;23(11):e25634. https:\/\/doi.org\/10.1002\/jia2.25634.","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"11919_CR18","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1097\/QAD.0000000000001452","volume":"31","author":"ET Montgomery","year":"2017","unstructured":"Montgomery ET, van der Straten A, Chitukuta M, Reddy K, Woeber K, Atujuna M, et al. MTN-020\/ASPIRE Study: Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159\u201367. https:\/\/doi.org\/10.1097\/QAD.0000000000001452.","journal-title":"AIDS"},{"issue":"3","key":"11919_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/QAI.0000000000002028","volume":"81","author":"A van der Straten","year":"2019","unstructured":"van der Straten A, Browne EN, Shapley-Quinn MK, Brown ER, Reddy K, Scheckter R, et al. First impressions matter: how initial worries influence adherence to the Dapivirine vaginal ring. J Acquir Immune Defic Syndr. 2019;81(3):304\u201310. https:\/\/doi.org\/10.1097\/QAI.0000000000002028.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"11919_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jpba.2016.03.023","volume":"125","author":"P Spence","year":"2016","unstructured":"Spence P, Nel A, van Niekerk N, Derrick T, Wilder S, Devlin B. Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence. J Pharm Biomed Anal. 2016;125:94\u2013100. https:\/\/doi.org\/10.1016\/j.jpba.2016.03.023.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"11919_CR21","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s10461-018-2261-8","volume":"23","author":"BS Mensch","year":"2019","unstructured":"Mensch BS, Richardson BA, Husnik M, Brown ER, Kiweewa FM, Mayo AJ, et al. vaginal ring use in a phase 3 microbicide trial: a comparison of objective measures and self-reports of non-adherence in ASPIRE. AIDS Behav. 2019;23(2):504\u201312. https:\/\/doi.org\/10.1007\/s10461-018-2261-8.","journal-title":"AIDS Behav"},{"issue":"11","key":"11919_CR22","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1080\/13691058.2018.1552989","volume":"21","author":"M Chitukuta","year":"2019","unstructured":"Chitukuta M, Duby Z, Katz A, Nakyanzi T, Reddy K, Palanee-Phillips T, et al. Negative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa. Cult Health Sex. 2019;21(11):1209\u201324. https:\/\/doi.org\/10.1080\/13691058.2018.1552989.","journal-title":"Cult Health Sex"},{"issue":"4","key":"11919_CR23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1080\/13548506.2014.953962","volume":"20","author":"R Dudhia","year":"2015","unstructured":"Dudhia R, Kagee A. Experiences of participating in an antiretroviral treatment adherence club. Psychol Health Med. 2015;20(4):488\u201394. https:\/\/doi.org\/10.1080\/13548506.2014.953962.","journal-title":"Psychol Health Med"},{"issue":"Suppl 4","key":"11919_CR24","doi-asserted-by":"publisher","first-page":"21649","DOI":"10.7448\/IAS.20.5.21649","volume":"20","author":"PR Tsondai","year":"2017","unstructured":"Tsondai PR, Wilkinson LS, Grimsrud A, Mdlalo PT, Ullauri A, Boulle A. High rates of retention and viral suppression in the scale-up of antiretroviral therapy adherence clubs in Cape Town, South Africa. J Int AIDS Soc. 2017;20(Suppl 4):21649. https:\/\/doi.org\/10.7448\/IAS.20.5.21649.","journal-title":"J Int AIDS Soc"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-11919-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-021-11919-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-11919-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T16:04:17Z","timestamp":1636387457000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-021-11919-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["11919"],"URL":"https:\/\/doi.org\/10.1186\/s12889-021-11919-x","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"assertion":[{"value":"11 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the MTN-020\/ASPIRE study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All study participants consented to trial participation per site-specific informed consent forms modified from sample informed consent forms included in the , which is available at . The study was approved by the following Institutional Review Boards\/Ethics Committees and Drug Regulatory Authorities: Prevention Sciences Research Committee of the US National Institute of Allergy and Infectious Diseases; US Food and Drug Administration; National Health Sciences Research Committee of Malawi; Johns Hopkins University Bloomberg School of Public Health Institutional Review Board; University of North Carolina at Chapel Hill Institutional Review Board; Pharmacy, Medicines and Poisons Board of Malawi; University of Cape Town: Human Research Ethics Committee; Biomedical Research Ethics Committee University of KwaZulu-Natal; South African Medical Research Council Ethics Committee; Human Research Ethics Committee: (Medical), University of Witwatersrand, Johannesburg; Medicines Control Council of South Africa; Joint Clinical Research Centre Institutional Review Board; Uganda National Council for Science and Technology; Johns Hopkins University School of Medicine Institutional Review Board; National Drug Authority of Uganda; Medical Research Council of Zimbabwe; Committee on Human Research, University of California - San Francisco; Joint Parirenyatwa Hospital and College of Health Sciences Research Ethics; Research Council of Zimbabwe; Medicines Control Authority of Zimbabwe.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2041"}}